首页> 外文期刊>Cardiovascular Research >Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)
【24h】

Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P)

机译:高密度脂蛋白(HDL)相关的鞘氨醇-1-磷酸(S1P)的抗动脉粥样硬化作用

获取原文
获取原文并翻译 | 示例
           

摘要

Numerous epidemiological studies documented an inverse relationship between plasma high-density lipoprotein (HDL) cholesterol levels and the extent of atherosclerotic disease. However, clinical interventions targeting HDL cholesterol failed to show clinical benefits with respect to cardiovascular risk reduction, suggesting that HDL components distinct from cholesterol may account for anti-atherogenic effects attributed to this lipoprotein. Sphingosine-1-phosphate (S1P) - a lysosphingolipid exerting its biological activity via binding to specific G protein-coupled receptors and regulating a wide array of biological responses in a variety of different organs and tissues including the cardiovascular system - has been identified as an integral constituent of HDL particles. In the present review, we discuss current evidence from epidemiological studies, experimental approaches in vitro, and animal models of atherosclerosis, suggesting that S1P contributes to atheroprotective effects exerted by HDL particles.
机译:大量的流行病学研究表明,血浆高密度脂蛋白(HDL)胆固醇水平与动脉粥样硬化程度之间存在反比关系。但是,针对HDL胆固醇的临床干预措施并未显示出降低心血管风险的临床益处,这表明不同于胆固醇的HDL成分可能解释了这种脂蛋白的抗动脉粥样硬化作用。鞘氨醇-1-磷酸酯(S1P)是一种鞘糖脂,它通过与特定的G蛋白偶联受体结合并在包括心血管系统在内的各种不同器官和组织中调节多种生物学反应而发挥其生物学活性。 HDL颗粒的组成部分。在本综述中,我们讨论了流行病学研究,体外实验方法和动脉粥样硬化动物模型的最新证据,表明S1P有助于HDL颗粒发挥抗动脉粥样硬化作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号